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RIASSUNTO 
Le cellule staminali del liquido amniotico (AFSCs) possono essere isolate dal 
liquido amniotico in seguito ad amniocentesi cui le donne incinte si 
sottopongono durante il secondo trimestre della gravidanza, questa popolazione 
è già stata caratterizzata e condivide proprietà comuni fra le cellule staminali 
embrionali e le cellule staminali adulte mesenchimali. Le AFSCs possono essere 
identificate tramite specifici marcatori; in questo studio – com’è già stato 
pubblicato – si è puntata l’attenzione sulla frazione positiva per CD117 (c-Kit). 
Queste cellule sono di grande interesse ai fini della medicina rigenerativa, 
considerando il loro potenziale di differenziamento e la relativa costante 
disponibilità, inoltre il recupero di cellule prenatali di origine autologa offre la 
possibilità di nuove strategie per curare i neonati con malformazioni congenite o 
altre malattie. 
In questo studio si è voluto esplorare la possibilità di isolare le AFSCs al termine 
della gravidanza (quindi al terzo trimestre, recuperando il liquido amniotico 
durante il parto). Sono stati investigati i fenotipi e le potenzialità differenziative 
di entrambi i trimestri. Queste cellule hanno anche un grande potenziale poiché 
possono essere mantenute in cultura e il loro numero significativamente 
aumentato per successive applicazioni. 
L’ipossia è un ben conosciuto fattore che influenza la coltura delle cellule 
staminali; coltivare le cellule in basse tensioni di ossigeno è già stato dimostrato 
avere un effetto benefico su altre cellule staminali, è stato quindi deciso di 
provare quest’approccio per migliorare l’espansione delle AFSCs. 
Sono stati effettuati esperimenti in vivo per verificare il potenziale angiogenico 
delle AFSCs. 
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ABSTRACT 
Amniotic Fluid Stem Cells (AFSCs) can be isolated from the amniotic fluid after 
amniocentesis that pregnant women undergo during the second trimester of 
pregnancy, this population has already been characterised and share common 
features between embryonic stem cells and adult mesenchymal stem cells. AFSCs 
are identified by specific markers; this study – as already published – focuses on 
the CD117 (c-Kit) positive fraction of AFSCs. Those cells are of great interest for 
regenerative medicine purposes considering their potential of differentiation and 
the relative constant availability, moreover retrieving prenatal autologous cells 
can offer new strategies for new-borns with congenital malformations or 
diseases. 
This study was intended to explore the possibility of isolating AFSCs at term of 
pregnancy (so at the third trimester, retrieving the amniotic fluid during 
delivery). Comparison on phenotype and test of potential for different lineages 
differentiation has been investigated on cells from both trimesters. These cells 
have a great potential also because they can be kept in culture and their number 
significantly increased for successive applications. 
Hypoxia is also a well-known factor that influence culture of stem cells, 
cultivating cells at lower oxygen tension has already demonstrated various 
beneficial effects on other stem cells so it has been decided to try this approach 
to ameliorate the expansion of AFSCs. 
In vivo experiments were performed to verify in vitro results on angiogenic 
potential of AFSCs. 
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INTRODUCTION 
 
The main goal of regenerative medicine is to restore a normal functionality and 
structure in a tissue after an injury, a pathologic debilitation/condition or a 
congenital malformation. 
In the human body tissues are continuously maintained in a homeostatic state by 
self-reparative processes that contribute to the growth and subsequently to the 
lifetime of an adult person. This regenerative capacity decline with the lifespan 
and eventually is poorly able to sustain its role in elder people, pathological 
conditions can also diminish or inhibit this property. Obviously in presence of a 
genetic disease the cells that are going to substitute the “malfunctioning” ones 
will have the same impairment and so the defect is not replaced but maintained 
(and at some point this futile regeneration will stop for lack of cells). Also in case 
of congenital malformations usually the body is not able to repair the 
compromised state occurred in the development. 
 
The “R3” paradigm 
Therapeutically speaking these concepts can be unified under the “R3” paradigm 
that state a balance of three repair strategies: rejuvenation, replacement and 
regeneration (Nelson et al., 2008) (Figure 1). 
• Rejuvenation: it’s the most basic process in which self-renew occur; resident 
tissue specific precursors cells take the place of naturally compromised or 
senescent cells in the tissue, this allows to maintain a fully functional 
organism able to be make front to the stress and tolerate a normal survival. 
This process allows us to recover after an injury but with limitations due to 
tissue-specific progenitors capacity. Acting on this mechanism will boost the 
response of an organism to repair itself with its own precursor cells: like using 
pharmacological treatments to induce resident dormant cells to reactivate 
and contribute to healing processes (Surani and McLaren, 2006). This strategy 
is somehow limited, for example it is unlikely to envisage this kind of strategy 
to restore heart muscle after a critical event like a myocardial infarction. 
• Replacement: maybe this is the most familiar strategy know, the most 
common example is transplantation of an organ to replace one that failed its 
role; obviously this most familiar strategy has also a series of problematic like 
the low availability of “replacement parts” and the difficulty to match a 
donor-host transplant without risk of rejection. In this field cell-based 
replacement is a promising strategy, the aim is to recreate a transplantable 
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tissue(s) using precursors from a donor or the patient itself (avoiding 
rejection risks) and manufacture in vitro a new transplantable organ or a part 
of it. 
• Regeneration: a step forward in respect of replacement strategies, this refers 
to the engraftment of progenitor cells able to grow and differentiate directly 
in vivo and restore the damaged tissue. An extraordinary example of this 
approach are haematopoietic stem cell transplantations, in this procedure 
some precursors derived from a donor can be injected inside a host and there 
they will repopulate the bone marrow niche and restore the ability to 
generate all cells in the haematopoietic system. The main problem of this 
strategy is to find a specific cell population able not only to restore damaged 
tissue but also to restore a functional reserve of precursors that will remain in 
the regenerated site. 
All these point have greatly benefitted from the discoveries made in the field of 
stem cell research. It is clear how the two are strictly linked, providing 
information on the identity and the mechanism of differentiation about cells 
compatible for clinical approaches. 
 
Figure 1 an exemplificative scheme of the R3 paradigm (Nelson et al., 2008) 
Stem cell types and sources 
A stem cell is characterised by simply two criteria: ability to divide maintaining 
this property of duplication throughout generations and capacity to differentiate 
into one or more specialised cell types. 
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The first property is called “self-renewal” and could be theorised and observed 
already two centuries ago when the concept of “cell” as the basic unit of life was 
determined. Notably stem cells maintain the pool of undifferentiated cells after 
each division, two types of cell division are observed: asymmetric and symmetric 
(Figure 2 B). Asymmetric division produce two different daughter cells from a 
father stem cell, one will be equal to the original and the other will become a 
differentiated cell losing the stem cell criteria. Symmetric division (or stochastic 
differentiation) implies that one father stem cell produce two identical daughter 
cell that are differentiated, at the same time, to maintain the original pool of 
undifferentiated cells, another stem cell in the tissue will undergo a symmetric 
division producing two daughter stem cells (Magnus et al., 2008). 
The second property is called “potency” and was classified in different manners 
during the years; nowadays a common classification is based on how broadly a 
single cell is able to differentiate (Figure 2 A): 
• Totipotent: cells able to form all embryonic and extraembryonic types of cell; 
when a sperm fertilises an egg a zygote is formed, this is the first totipotent 
cell and maintain its characteristics for the first few divisions (until the 16-cell 
stage of the morula). 
• Pluripotent: these cells can differentiate into all the three germ layers 
(endoderm, mesoderm and ectoderm) and give rise to all types of foetal and 
adult cells; however they cannot form a developing embryo because they 
lose the ability to form extraembryonic tissue such as the placenta. 
• Multipotent: stem cells able to differentiate into a limited (yet various) family 
of cells, meaning they cannot originate cells from all the three germ layers 
(e.g. human foetal liver multipotent progenitor cell able to differentiate as 
liver and as fat, cartilage, bone, and endothelial cells (Dan et al., 2006)). 
• Oligopotent: is the characteristic of cells sometimes called “progenitor cells”, 
thy have the ability to differentiate into few cell types, an example of 
progenitor are Vascular Stem Cells that are able to become endothelial but 
also smooth muscle cells (Klein et al., 2011). The main difference of 
progenitor cells compared to stem cells is that the first can divide only a 
limited number of times, for that reason there is still controversy about 
calling them real stem cells. 
• Unipotent: those cells are also called “precursor cells”, they have lost almost 
all their potency, they retain the self-renew ability but they can differentiate 
in only one cellular type. 
As already told, the main problem is to find the best cellular source for 
regenerative medicine aims, based on: grade of potency in regard of the 
purposes, availability from donors and easiness of isolation methods. 
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Figure 2 A: potency degree of stem cells. B: the two main type of division to guarantee the stem cell pool 
survival adapted from (Magnus et al., 2008; Kyo et al., 2011). 
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Embryonic stem cells 
Stem cells can be obtained from a host at different times in his life, starting from 
the very moment of conception and ending at the end of life itself. Potency is 
greatly influenced by development and so more potent stem cells are found only 
in early stages of embryonic divisions. 
Embryonic Stem (ES) cells comprise totipotent stem cells if they derive from the 
whole fertilised egg before the formation of the blastocyst or pluripotent stem 
cells if they came from Cells of the Inner Mass (IMC). In both cases they are 
normally excluded to be considered a good source of cells: using those cells 
means destroy a zygote, which raises a series of ethical questions. 
In 1981 the first embryonic stem cell line were derived from inner cell masses of 
late blastocysts (Evans and Kaufman, 1981; Martin, 1981) and after that for 
almost twenty years scientist tried to obtain a human ES cell line. 
In 1998 Thomson and colleague were able to do that, obtaining five ES cell lines 
starting from a high number of fresh or frozen human embryo produced but not 
used during in vitro fertilisation procedures (Thomson, 1998). 
In 2006 there was then the discovery of a technique that permits to derive ES 
cells from single blastomers without harming the embryo development 
(Klimanskaya et al., 2006).  
Even with those great steps the process for obtaining ES cells is still laborious, 
time demanding, with a low yielding and mostly it is limited by the low oocytes 
availability. 
Somatic Cell Nuclear Transfer 
The nucleus of an unfertilised oocyte can be taken out and replaced with another 
from a different cell, this is called Somatic Cell Nuclear Transfer (SCNT). These 
experiments initiated originally with nuclei from Xenopus extracted from 
embryonic cells and then implanted into a new egg, leading to a new developing 
embryo (Briggs and King, 1952; Gurdon et al., 1958). Many years later it was also 
demonstrated that not only embryonic cells but also adult and so terminally 
differentiated cells permits this process to obtain a new frog larvae (Gurdon, 
2006; Pasque et al., 2011).The proof of concept about these experiments is that 
somehow the oocyte cytoplasmic environment is able to reprogram the somatic 
nucleus to a pluripotent state and erase all the epigenetic imprinting acquired 
during development. These embryos if implanted will eventually leads to a clone 
of an already existing creature – the donor of the nucleus – as widely known 
from the experiments on sheep resulting in “Dolly”, the first cloned being 
produced from an adult mammal cell (Campbell et al., 1996). 
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Shortly after the discovery of SCNT from Gurdon and colleagues, in 2000 for the 
first time mouse ES cells were isolated from a cloned blastocyst after nuclear 
transfer (Munsie et al., 2000). This was aimed to establish a procedure to obtain 
ES cells and then transfer the technique to possible human applications in order 
to obtain pluripotent patient-specific replacement cells. Unfortunately 
experiments on primates revealed that SCNT is really hard to achieve, early 
experiments showed a blockage to early-cleavage stage on monkey embryos 
(Pan et al., 2012). After improvements in the technique, two ES cell lines were 
isolated from over 300 starting oocytes, displaying ES morphology, pluripotency 
markers and teratoma formation capability when injected in vivo (Byrne et al., 
2007), this was the first result confirming that cloning in human might be 
possible. 
As already discussed for primates, also human SCNT presented a lot of technical 
challenges, probably the manipulation of the oocyte during the nuclear transfer 
impair the factors inside the cytoplasm and leads to an early arrest of blastocyst 
divisions (Chung et al., 2009b). Up to now the only successful result in obtaining 
ES cells from SCNT in human was achieved by Noggle and colleagues: they 
introduced the nucleus of a somatic cell inside an egg without taking first out the 
oocyte’s nucleus (Noggle et al., 2011). This leads to a triploid set of chromosome 
not suitable for perspective applications in human medicine; also, without 
detailed analysis of gene profiling and epigenetic signature remodelling, these 
results are to take with proper caution. 
Even with those discoveries SCNT as a source for ES cells for regenerative 
medicine is not a very good choice if someone consider the efficiency of the 
process (the huge numbers of starting oocytes required to obtain few 
pluripotent cells) moreover this technique has all a series of ethical concerns. 
 
Adult cells 
Induced Pluripotent Stem cells 
Avoiding all kinds of ethical issues and starting from an easily accessible source of 
cells, in 2006 Takahashi and Yamanaka first developed a technique for obtaining 
ES-like cells from mouse somatic cells without the needs of an oocyte. Inspired 
by the work on SCNT they hypothesised that some reprogramming factors 
specific of ES cell could substitute the unique environment of the oocyte and 
thus reprogram a somatic cell without the need of SCNT. A series of transcription 
factors were transduced, via retroviral infection, into mouse fibroblasts and then 
culturing them under ES cell conditions (over Mouse Embryonic Fibroblasts 
(MEF) feeder-layer and supplementing the culture with Leukaemia Inhibitory 
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Factor (LIF, a molecule responsible for cell growth and inhibition of 
differentiation)) resulted in the formation of colonies with pluripotency 
characteristics. Subsequently, after an exclusion process, four transcription 
factor (i.e. Oct3/4, Sox2, c-Myc, and Klf4) were found to be sufficient in inducing 
this transformation. The obtained cells (called iPS (induced Pluripotent Stem) 
cells) show a morphology, grow and markers expression typical of ES cells, they 
are also able to form teratoma when injected in vivo (formation of tissue from all 
the three germ layers) (Klimanskaya et al., 2006) and if injected into a dividing 
blastocyst they generate a chimera with the blastomers and contribute to the 
formation of the embryo (Wernig et al., 2007). 
These results were subsequently obtained also with human fibroblasts by 
transfecting them with the homologous transcription factors of mice (Takahashi 
et al., 2007). 
The first striking thing about this approach is the origin of material, potentially 
almost each cell of the organism can be reprogrammed into an iPS cell, this 
means obtaining samples with non-invasive procedures from donors (e.g. a 
simple skin biopsy but someone would also go further and say that starting cells 
could be obtained even from a cheek swab (Cyranoski, 2007)). The second thing 
is that with this method one can generate replacing parts for each cell type of 
the body, regardless of the original material. 
Even with those promising perspectives there are some issues related to iPS cells 
generation. First of all there is the problem of the reprogramming, the four 
reprogramming factors constructs are usually delivered with retrovirus or 
lentivirus (Park et al., 2008), this “integrational” strategies cause the insertion of 
the constructs inside the genome of the original cell so without the possibility of 
take out the factors once they are integrated. Some strategies using inducible 
promoters (e.g. doxycycline controlled expression (Carey et al., 2009)) or 
excisable transcription factors (using constructs flanked with LoxP regions that 
allows the excision by CRE recombinase enzyme (Sommer et al., 2010)) have 
been developed but even with controllable expression of the exogenous factors 
there is one problem that remain bounded to this integrational strategy and this 
is “insertional mutagenesis”: this phenomenon is the result of random events 
where the constructs integrate inside the genome disrupting the function of 
important genes implied in cell maintenance, also there is the possibility that 
insertion occurs in sites of some endogenous oncogenes. 
Numerous strategies are been investigated to find a method with no DNA 
integration but so far there has been a lot of results with “low probability” of 
genomic integration and the only few “integration free” methods have very low 
efficiency or require too much complicated culture techniques (see Table 1). 
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DELIVERY METHOD CHARACTERISTICS GENOMIC 
INTEGRATION 
HIGH 
EFFICIENCY 
TECHNICAL 
ISSUES 
Retrovirus Limited to dividing cells, 
possibility of viral transgene 
reactivation. 
+ +/- + 
Lentivirus Inducible transgene expression, 
excision possible. 
+ + - 
ΦC31 phage 
Integrase 
Site-specific DNA integration 
+ + + 
Transposon Temporary integration. (+) + +/- 
Sendai Virus No integration but complex 
method. 
- +/- + 
Minicircle 
vector 
Low efficiency. 
+/- - + 
Plasmid Very low possibility of genomic 
integration but also very low 
efficiency. 
(-) - - - 
Synthetic 
mRNA 
Require continuous transfection 
for up to 2 weeks. 
- + + + 
Protein Recombinant 
proteins of the four factors, very 
low efficiency. 
- - - + 
Table 1. Adapted from (Hussein and Nagy, 2012; Mochiduki and Okita, 2012). 
Whether a full conversion to a pluripotent state or not is achieved with one of 
these methods, there are some issues related to the generation of iPS cells. One 
should consider that, starting from a somatic cell, there is the possibility of “bring 
back” mutations developed by the adult cell during its development. Another 
aspect to be considered in the iPS cells generation process is that of epigenetic: 
even if an adult cell does not present mutations that could alter its fate during 
reprogramming, there are certain boundaries by which the pluripotency is not 
fully achieved. After differentiation into a specific cell lineage, some genome loci 
are not more accessible and became silenced, so if a cell is brought back to the 
pluripotent state, and then induced to differentiate towards another lineage, it is 
not clear to which extent this process is effective and what are the limits of 
generating other cell types with different fate pathway of than the original cell 
history. A lot of controversies are present nowadays among scientists about 
genetic imprinting and capability of iPS cells (Figure 3). 
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Figure 3 resuming studies on 
comparison between iPS and ES cells 
(Sindhu et al., 2012). 
 
Interestingly SCNT is able to 
produce cells that from the 
transcriptional point of view 
are indistinguishable from ES 
cells (Brambrink et al., 2006), 
also the DNA analysis of 
methylation sites reveals a 
high similarity profile, iPS cells 
instead show an epigenetic 
memory of the originating cell 
(Kim et al., 2010) and 
different gene expression 
signatures (Chin et al., 2009), 
rising questions on their 
application for regenerative 
medicine purposes. 
 
Direct Reprogramming 
Another important point in 
cell reprogramming is about 
“direct reprogramming”. Even 
before the discovery of the 
four genes to revert cells to a 
pluripotent state, it was observed that it is possible to convert one cell type into 
another without passing through a pluripotent state. Taylor and Jones first 
demonstrated that fibroblasts exposed in culture to a hypomethylating agent 
(called 5-azacytidine) spontaneously differentiate into adipocytes and myocytes 
(Taylor and Jones, 1979).Then another important step was the finding that 
expressing the basic helix-loop-helix transcription factor MyoD inside fibroblasts 
will induce them to transform into contracting myocytes (Davis et al., 1987). 
Notably a full conversion could not be achieved if MyoD was expressed inside 
cells originating from a different germ layer (Weintraub et al., 1989). It was just 
until a couple of years ago that nobody was able to convert adult cells to other 
cell types if not to those closely related to the originals; in 2010 it was 
demonstrated that fibroblast (mesoderm origin) expressing three transcription 
factors (Brn2, Ascl1, and Myt1l) could be converted into functional neural cells 
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(ectoderm origin) (Vierbuchen and Wernig, 2012); from that moment on direct 
reprogramming was achieved by expressing different transcriptional factors and 
generating new cell types from not related somatic cells of origin (Figure 4). 
 
Figure 4 Direct reprogramming successful factors and specific lineage conversion (Vierbuchen and Wernig, 
2012). 
Mesenchymal stem cells 
Cells present in the bone marrow (BM) are mainly divided in two categories: 
Haematopoietic Stem Cells (HSC) and stromal supportive cells; where the first 
type has a clear identification (stem cells capable of originating all the cells in the 
haematopoietic system) the second group are quite heterogeneously described. 
Pioneer experiments in the 19th century showed that BM transplantation in 
different anatomical regions generated de novo ectopic bone and marrow 
(Goujon, 1869). Almost a century later Tavassoli and Crosby demonstrated the 
presence of osteogenic progenitors inside BM (Tavassoli and Crosby, 1968) but 
these progenitors were fully identified as BM and not bone derived only in 1974 
by Friedenstein and co-workers; they described those cells as a “non-
haematopoietic” source of cells inside the stromal portion of the marrow 
capable of clonogenic activity in an in vitro assay called Colony-Forming Unit 
Fibroblast (CFU-F) (Friedenstein et al., 1974). They called these “BM stromal 
cells” in light of later demonstration that in the bone they function as a 
supportive tissue for HSC, later they also demonstrated that non only bone but 
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also cartilage, adipose and fibrous tissue were generated by those cells when 
injected in vivo (Owen and Friedenstein, 1988). 
A new search begun to find multipotent stem cells resident in adult tissues 
containing stroma with function of mechanical and biological support. Soon 
enough BM stromal cells were found and isolated into a variety of other tissues 
like: adipose tissue, periosteum, synovial membrane, muscle, dermis, pericytes, 
blood, and trabecular bone (Tuan et al., 2003). 
These was demonstrated to be true not only in adult tissues but also in birth-
associated tissues like: placenta, amnion, umbilical cord, cord blood, and 
Wharton’s jelly (Hass et al., 2011). 
It was clear that calling those cells “BM stromal cells” was no more adequate, so 
in 1991 Caplan used for the first time the term “Mesenchymal Stem Cell” (MSC). 
Both definitions are quite misunderstandable in spite of different aspects 
(Porcellini, 2009): 
• Mesenchyme is an embryonic tissue of mesodermal origin that gives rise to 
haematopoietic cells and connective tissues: as already told, Mesenchymal 
Stem Cells (MSCs) “do not” differentiate into haematopoietic lineages. 
• Stromal cells are present in, and form, the connective tissue in which the 
functional cells carry out their role: it is quite evident that MSC also 
contribute to tissue functions, have an active role in tissue repair and 
maintenance. 
• MSC, even if derived not only from BM and demonstrated to have 
multipotent abilities, lack the capacity to reconstitute an entire organ: in light 
of that, someone suggested to change the meaning of the acronym to 
“Multipotent Stromal Cell”. 
After the fine characterisation of Friedenstein and colleagues about the ability of 
MSCs to differentiate into bone, cartilage and adipose tissue, other works 
demonstrated an even more broad potential of those cells. 
MSCs derived from different tissues displayed myogenic properties: they were 
able to differentiate into skeletal muscle cells (Ferrari et al., 1998), smooth 
muscle cells (Lee et al., 2006; Rodriguez et al., 2006) and also cardiac muscle cells 
(Planat-Benard et al., 2004). 
Differentiation into endothelial cells (Wosnitza et al., 2007; Heydarkhan-Hagvall 
et al., 2008) and hepatocyte-like cells (Seo et al., 2005) was also obtained with 
MSCs. 
More interestingly it was later demonstrated that MSCs have the capacity to 
differentiate in vitro towards neuron-like cells, specifically in dopaminergic 
neuron-like cells (Pacary et al., 2006; Scuteri et al., 2011); more importantly they 
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are also able to differentiate into mature astrocytes and neurons when 
implanted in the brain of neonatal mouse (Kopen et al., 1999). 
This major finding demonstrated that MSCs have the capability to go beyond the 
limit of proper multipotent stem cells: they are able to differentiate into tissue of 
germ layers other than mesoderm. 
After demonstrating the neuroectoderm potency of MSCs, soon came the 
demonstration that these cells can be induced to differentiate into insulin-
producing cells, making them a notable candidate for diabetes therapies (Limbert 
and Seufert, 2009). 
This intrinsic plasticity of MSCs is somehow heterogeneous, these multipotent 
cells isolated from different anatomical sources show disparity on the potential 
to differentiate in some lineage, a well-known example are MSCs isolated from 
the Umbilical Cord Blood (UCB-MSCs) that seem unable to give rise to advanced 
adipogenesis when cultured in specific media (see Figure 5) (Lee et al., 2012). 
 
Figure 5 MSC comparison of different potential. A: adipogenic differentiation as shown by Oil Red O 
pigment (red) uptake. B: hepatic differentiation as shown by indocyanine green (light green) uptake. a to h: 
in order there are amnion MSCs, chorionic villi MSCs, chorionic villi MSCs, Wharton’s jelly MSCs, adipose 
derived MSCs, bone marrow MSCs, umbilical cord MSCs and control fibroblasts (Lee et al., 2012). 
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Surface marker identification by flow cytometry reveals a consistent phenotype 
among MSCs from different tissues, even if some slight variation in terms of 
percentage of positivity is observed and some specific markers are expressed 
only in one cell type. For example CD49d is found expressed in Adipose-Tissue-
derived MSC (AT-MSCs) compared to BM-MSCs (where instead CD106 is 
expressed, see Figure 6). 
 
Figure 6 A: flow cytometry graphs showing expression of markers on various MSCs and HS68 fibroblasts 
(Wagner et al., 2005). B: table showing percentages of flow cytometric analysis (Kern et al., 2006). 
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Another point is related to the ability to isolate MSCs starting from different 
tissues, for example the ability to form CFU-F described by Friedenstein and co-
workers can be used to evaluate the score of MSCs obtainable; using this type of 
comparison BM-MSCs and AT-MSCs show similar results whereas UCB-MSCs 
seems more difficult to obtain. 
Following the continuous search for new sources of MSCs in new tissues – more 
amenable to obtain, and maybe more powerful in term of potency – the 
International Society for Cellular Therapy (ISCT) defined some rules that should 
be followed to identify new types of MSCs (Dominici et al., 2006). 
• First of all the cells should be able to adhere on the plastic surface when 
cultured in standard conditions. 
• They should possess a specific phenotype characterised by flow cytometry. 
o expression of CD105, CD73 and CD90 (with at least 95% of positive cells) 
o no staining for CD45, CD34, CD14, CD11b, CD79a, CD19 or Human 
Leukocyte Antigen (HLA) class II (tolerated values < 2%). 
• Cells have to be able to generate in vitro osteoblasts, adipocytes and 
chondroblasts (this should be demonstrated by specific stainings). 
Another interesting and really appealing aspect of MSCs for regenerative 
medicine purposes is about their immunoprivileged as well as 
immunosuppressive properties. 
MSCs display a peculiar phenotype in terms of molecules on the cell membrane. 
First of all they have low levels of MHC class I antigens (almost no HLA type A, B 
or C detectable) and a low presence/activity of the internal proteasome-related 
antigen processing machinery (Le Blanc et al., 2003). As already told they also 
lack the presence of HLA class II molecules, components of the Major 
histocompatibility complex (MHC) class II, a typical molecule found on Antigen 
Presenting Cells (APCs). They also lack the FAS Ligand (CD95L), CD40 or CD40L 
(implied in recognition on APCs by CD4+ helper T cells), B7-1 and B7-2 (also called 
CD80 and CD86) that are known as co-stimulators for T cell activation (so if MSCs 
lack these molecules the only way to be exposed to CD8+ cytotoxic T cells is via 
signalling by helper T cells or other cytokines) (Deans and Moseley, 2000). 
On the other hand MSCs express a variety of adhesion molecules and are able to 
migrate into injured tissues after adhering to endothelial cells (Chamberlain et 
al., 2007), this migration can be caused also if MSCs are stimulated by ligands of 
Toll Like Receptor (TLRs) that these cells express on their membrane and it has 
been demonstrated that these TLRs are implicated in proliferation, 
differentiation, migration, survival, and immunosuppressive abilities of MSCs. 
The immunomodulation effect exerted by MSCs is a relatively new field in which 
it is now becoming clear how these cells interact with the immune system. 
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As already told, TLRs expressed on the surface acts in MSCs behaviour, it has 
been suggested that this is the start of a downstream signalling that ultimately 
results in release of soluble factors like indoleamine 2,3 dioxygenase (IDO), 
prostaglandin E2 (PGE-2) or nitric oxide (NO), all demonstrated to have an effect 
in the immune system (see Figure 7) (DelaRosa and Lombardo, 2010). 
 
Figure 7 Immunomodulatory properties and soluble factors related to MSCs (Gebler et al., 2012). 
It has already been discussed about what surface molecules MSCs do not present 
and so why they are immune-tolerated, but also they present molecules that 
directly influence the immune system. Among these we have the presence of 
HLA-G (Human Leukocyte Antigen class G), a common antigen found in organs 
that have an immune-privileged environment (e.g. testes in males and ovaries in 
females, also some cells during embryogenesis) and acts mainly via inhibition of 
APCs. 
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A variety of other factors released by MSCs are related to specific cell 
subpopulations inhibition, both from innate and adaptive immunity (Shi et al., 
2011). 
Given all these considerations one should clearly understand the interest of 
regenerative medicine towards MSCs. Not only they are an appealing source for 
regenerating damaged or non-functional parts, with a good chance of not being 
rejected and to integrate with the patient, but they can also be used as a 
regulatory tool for creating a permissive environment for treated areas. 
They are nowadays many clinical trials about MSCs (see Figure 8), one of the few 
in phase 3 (final testing phase where the treatment is given to large groups of 
people) involves treatment with MSCs for creating an immunosuppressant 
environment to treat GVHD (Graft-Versus-Host Disease) in steroid refractory 
acute cases and in newly diagnosed acute GVHD (Kebriaei and Robinson, 2011). 
 
Figure 8 Actual clinical trials regarding MSCs (Trounson et al., 2011). 
Foetal stem cells: amniocytes 
The amniotic fluid (AF) is an aqueous environment contained by the membrane 
“amnion” that surrounds the foetus during development; it has a function of 
sustain for the embryo and protect it from outside injuries like movements or 
blows but it also allow to maintain a constant temperature (Underwood et al., 
2005). Among other functions it allows the passage of nutrients from the 
placenta to the foetus that can absorb them before skin keratinisation (Jauniaux 
et al., 1999), but also after that it is a source of nutrients and also hormones that 
can be assimilated via foetal swallowing (Mulvihill et al., 1986). It was also known 
that AF contains some cells, even if not fully identified their source it is taught a 
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shared origin from both embryonic and extra-embryonic tissues, those cells 
derive from all the three germ layers (Cremer et al., 1981). AF cells – or 
amniocytes – were not of great interest considering their identities of fully 
differentiated and non-replicating cells but then, in the 1990s, some 
subpopulation with proliferating behaviour where isolated for the first time, then 
there were demonstrated to be some kind of haematopoietic progenitor 
(Torricelli et al., 1993) and some year later also cells with myogenic potential 
were identified (Streubel et al., 1996). 
In the early 2000s an MSC-like population was first described based on the 
proliferation rate and some marker expression (Kaviani et al., 2001), these cells 
were phenotypically more characterised and their multilineage potential was 
verified, giving them a full title of MSCs (In 't Anker et al., 2003). 
The great interest on cells deriving from AF is related mainly for the source per se 
considering that the AF is easily obtainable from procedures that pregnant 
women undergo around the second trimester of gestation, namely 
amniocentesis and amnioreduction. During the first procedure, few millilitres (2-
3 mL) are available for research; differently during amnioreduction, which is 
usually performed during the third trimester in case of polydramnios, more than 
500 mL can be retrieved for cells extraction. 
This source of cells overcomes the ethical issues related to the use of human 
embryonic cells because of their foetal but non-embryonic origin; amniocytes 
also make front to the donor associated morbidities of postnatal tissue biopsies. 
As reviewed by Prusa and colleagues, the cellular component of AF consist of a 
heterogeneous pool of subpopulations different for morphological and also 
characteristics in culture (Prusa and Hengstschlager, 2002). When an 
amniocentesis sample is cultured in proper conditions, viable cells could be 
identified both attached to the surface of the culture material and some other 
floating in the medium. The adherent fraction normally takes up to four days to 
show up, meaning the cells need some time to adapt in the new environment, 
inside these cells we have some cell that do not proliferate and other as already 
told that are able to replicate and form colonies like those observed for MSCs. 
These colony-forming cells are also a heterogeneous population that include: 
• epitheloid (E-type) cells: have the classical morphology and form colonies 
typical of epithelial cells, soon after the beginning of the culture they stop 
replicating and disappear through passages. 
• amniotic fluid specific (AF-type) cells: they persist along different passages in 
culture, they present a spindle-shaped morphology, they are believed to 
originate from trophoblastic tissue as they produce estrogen, human 
chorionic gonadotropin and progesterone. 
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• fibroblastic (F-type) cells: the show up in culture al later passages and not 
every sample is able to generate those types of cell. 
Both AF and F-type cells share the same MHC phenotype (no HLA class II and 
low levels of HLA class I molecules) with MSCs. 
Amniocytes have been categorised “between” ES cells and adult stem cells; they 
share a more potent state compared to MSCs because they have been 
demonstrated able to differentiate into a more broader range of cell types 
(including all three germ layers): osteogenic, chondrogenic, adipogenic, hepatic, 
myogenic, renal, and more importantly into hematopoietic lineages (In 't Anker 
et al., 2003; Tsai et al., 2004; Bossolasco et al., 2006; Kim et al., 2007; Kolambkar 
et al., 2007; De Coppi et al., 2007; Perin et al., 2007; Perin et al., 2010; Siegel et 
al., 2009; Siegel et al., 2010; Ditadi et al., 2009; Hauser et al., 2010). 
Considering their characteristics, amniocytes are now considered to contain a 
pluripotent fraction and so they are also called AF Stem Cells (AFSCs). Given the 
importance of standardise experiments, and be sure to work on the same cellular 
type, identification based solely on morphology is not desirable; there are four 
main techniques performed to isolate amniocytes nowadays (see Figure 9): 
• Single-step: the cellular fraction of AF is put in culture and left undisturbed 
for one up-to three weeks without medium change (In 't Anker et al., 2004; 
Antonucci et al., 2009). 
• Two-step: five days after starting the primary culture unattached cells are 
retrieved and cultivated further (Tsai et al., 2004). 
• Selection: a specific antigen is used for positively identify a specific 
population within the amniocytes pool and isolate it (De Coppi et al., 2007). 
• Starter-cell: fibroblastoid colonies can be selectively cloned after their 
appearance and characterised later on (Phermthai et al., 2010). 
Given these four methods it is important to notice that cell potential referred to 
in vitro differentiation protocols, if tested from a heterogeneous pool, may 
derive from already committed progenitors inside the sample rather than obtain 
differentiation of AFSCs. It is then clear that the only two specific methods, to 
identify with a certain confidence “real” AFSCs, are those based on positive 
antigen selection or clonal expansion. The selection of specific antigen on cells 
require a deep study to identify possible markers of pluripotency associated to 
specific cell types; on the other hand the starter-cell protocol have the advantage 
of produce more rapidly large quantities of cells but one should also consider 
that the method is time-consuming and also it later needs to characterise each 
clone (see Figure 10). 
INTRODUCTION 
 
23 
 
Figure 9 The four principal methods of culturing and selecting AFSCs (Klemmt et al., 2011). 
Figure 10 Growing curves of AFSCs deriving from different methods of isolation (Phermthai et al., 2010). 
One important thing about AFSCs’ origin: giving the fact that they are obtained 
from procedures before the end of the pregnancy, one could expand those cells 
and also store them for a future purpose of treat the same foetus/new-born 
where they came from. This is particularly intriguing because it would be a 
transplantation without the risk of rejection (giving the autologous source of the 
cells) and moreover if one consider pathologies like neonatal malformation it 
should be considered that in some cases it’s practically impossible to find a 
suitable replacement from a donor that fits the specific needs of an infant. 
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AFSCs could also be suitable for therapies aimed to cure genetic diseases 
incompatible with life; the autologous cells – the amniocytes – could be retrieved 
during gestation, genetically remodelled and then re-injected in-utero before 
delivery to correct the defect. 
Perinatal stem cells 
Amniotic fluid can also be retrieved from pregnant women undergoing caesarean 
section; after cutting through the uterine wall and exposing the amniotic sac, a 
syringe can aspirate the AF. 
In 2008 and later also in 2009 a group from Heilongjiang published two papers 
reporting the discovery of MSCs from third-trimester AF. You and co-workers 
reported that these cells were positive for the pluripotency marker OCT4 (one of 
the factors used by Yamanaka to reprogram fibroblasts to iPS cells) at gene 
expression and protein level, showed consistent surface markers with MSCs and 
demonstrated able to differentiate towards the osteogenic lineage. There are a 
lot of questions opened on their work: first of all the fail to give proof of OCT4 
presence at protein level because the immunofluorescence staining are not 
convincing; osteogenic differentiation is demonstrated only by RT-PCR and not 
by specific stainings for calcium deposition or osteoblasts markers; as a final 
point they use a “single-step” method to isolate the cells. 
Hypoxia 
Routine cell culture protocols are based on the fact that pioneer work of cellular 
growth seemed to confirm that ambient air was suitable. These studies 
concentrated more on the components of the culture milieu to substitute the in 
vivo environment (nutrients, pH, minerals, grow factors), giving poor importance 
to the gas status inside physiological tissues (Shooter and Gey, 1952). 
Later studies demonstrated that oxygen levels inside the human body are very 
dissimilar from that of the initial partial pressure of oxygen (or  pO2, referred also 
as “oxygen tension” when talking of gas in a solution like the blood) inhaled 
inside the lungs. Levels ranging from 2% to 9% (14-16 mm Hg) have been 
reported in vivo (seeFigure 11) (Brahimi-Horn and Pouyssegur, 2007). 
Recently some experiments demonstrated that, during in vitro culture, these pO2 
values are able to sustain the cells and so the oxygen tension of ambient air 
usually considered “normoxic” may not represent the physiological normoxia 
condition (Simon and Keith, 2008). 
However, when translated to the culture protocols of MSCs, contrasting results 
have been reported. This is probably due to a poor standardisation of culture 
conditions (media, oxygen tension, cell type and method of isolation). Although it  
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Figure 11 Hypoxic region of the human body related to specific stem cell niches (Mohyeldin et al., 2010). 
is generally accepted that hypoxic condition improve cell proliferation and 
maintain a more undifferentiated state (see Figure 12) (Tsai et al., 2012). 
About the differentiation potential of hypoxic-cultured MSCs there is a bit of 
confusion in literature. The majority of authors describe an inhibition of 
osteogenic differentiation in hypoxia but not all articles are concordant (Yang et 
al., 2011; Wagegg et al., 2012; Xu et al., 2012). About adipogenesis some authors 
report diminished achievement of differentiated adipocytes, other refer pre-
adipocyte stage blocking and some other report increased adipogenesis (Chung 
et al., 2009a). Condrogenesis is a well oxygen-depended process (Schipani, 2005) 
and MSCs in hypoxia seems to be more prone to form chondrocytes (Wang et al., 
2005; Xu et al., 2007). Also angiogenesis seems enhanced when culturing cells in 
low oxygen tension (Hung et al., 2007; Zhou et al., 2013).Finally MSCs cultured in 
an hypoxic ambient show a more migratory phenotype than normoxia-cultivated  
cells (Rosova et al., 2008). 
Figure 12 Effect of oxygen tension on MSCs proliferation. 
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AIM OF THE WORK 
Our group recently described and characterised a specific population of AFSCs 
inside the amniotic fluid retrievable from amniocentesis samples obtainable 
during the mid-gestational period (second trimester of pregnancy). This specific 
subset of amniocytes is characterised by expression of the surface marker c-Kit 
(or CD117, the Mast/stem cell growth factor receptor) (De Coppi et al., 2007). 
It was tried to standardise a protocol of isolation and expansion in vitro of this 
population, in hope that our technique will allow to obtain more comparable 
results among other groups working on the same subject. 
Another important aim pursued in this thesis project was trying to isolate and 
characterise amniocytes expressing c-Kit also from AF samples of the third 
trimester, collecting them at term during caesarean section. This was done not 
only to compensate the lack of information about this potential source of AFSCs 
(as already told, in literature there are few and quite ambiguous works on this 
subject) but also because obtaining pluripotent-like stem cells from a natural 
discarded tissue of the body would be extremely interesting and will avoid all the 
problematic related to donors and ethical concerns. 
After characterisation of third trimester AFSCs and making a comparison with the 
cells already known from the second trimester, the effect of hypoxic culture 
methods was also tested to see if there was an influence in the behaviour of our 
cells. 
Notably our approach is to expand in large scale the original population 
obtaining a great amount of cells usable for regenerative medicine approaches.
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MATERIALS AND METHODS 
Isolation of AFSCs 
Samples 
AF samples were obtained by two different gestational periods after informed 
consent of pregnant women: 
• Second trimester AF: samples were collected during routine amniocentesis 
performed at mid-gestation (16-18 weeks) for genetic screening purposes; 
one aliquot (usually 0.2 up to 2 millilitres) of the total aspirate were retrieved 
for research purposes. 
• Third trimester AF: from women undergoing eligible caesarean section, after 
cutting through the abdominal wall and the uterus, the amniotic sac was 
punctured with a syringe needle and AF was taken before rupturing the 
membrane. 
Seeding 
Pre-selection medium (or Chang B+C): 10 mL of sterile distilled water were used 
to resuspend Chang Medium C Lyophilized Supplement (IrvineScientific©) and 
this was let to equilibrate until no powder was visible inside the vial. 
Reconstituted Chang Medium C Supplement was added to the bottle of Chang 
Medium B Basal (IrvineScientific©) making a 100 mL final volume of medium 
called “Chang B+C”. This medium was completed with antibiotics (Penicillin and 
Streptomicyn, Gibco®) and also with L-Glutamine (2mM final) (Gibco®, P.N. 
25030) at the moment of use. 
 
Samples were filtered through a 70 µm nylon mash filter (BD©) and volume were 
adjusted with Phosphate Buffered Saline (PBS, Gibco®) for centrifugation. 
AF samples were centrifuged at 300 x g for 5 minutes. Supernatant were 
removed without disturbing the pellet. If erythrocyte contamination was 
observable, the pellet was then incubated with Auto Lyse PLUS (BioSource©) for 
lysing red cells following manufacturer’s specifications and washing steps. 
Cells were then resuspended in “Chang B+C” medium and seeded over a glass 
coverslip of the size suitable for the inside of a 35 mm x 10 mm petri dish (BD 
Falcon©). 
The morphology of the cells was checked daily and medium change was 
performed every 5-7 days until clusters of cells with mesenchymal-like 
morphology started to grow. 
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Immune-selection 
After taking out the supernatant from the petri dish and wash twice with PBS, 
cells were detached with Trypsin 0.05% with EDTA and Phenol Red (Gibco®). 
Trypsin action was blocked adding 4 volumes of MEM Alpha (Gibco®) containing 
25% of FBS Fetal Bovine Serum (FBS, Gibco®), and cells were pelleted with a 
centrifuge at 300 x g for 5 minutes. 
Isolation was performed positively selection CD117 positive (C-Kit positive) cells 
using the MACS® CD117 MicroBead Kit and the other required instruments from 
Miltenyi Biotec©. Briefly: 
1. After removing the supernatant, cell pellet was resuspended in 300 μL of 
buffer (buffer composition as specified in manufacturer’s instructions). 
2. 100 μL of FcR Blocking Reagent and 100 μL of CD117 MicroBeads were added 
and mixed well. 
3. Incubation for 15-20 minutes at 4°C. 
4. An MS Column was placed on the Separator attached to the MultiStand and 
washed once with buffer. 
5. Cells were washed once adding 2 mL of buffer to the cell suspension and 
centrifuging at 300 x g for 10 minutes. 
6. After resuspension in 500 μL of buffer, immune-labelled cells were passed 
through the MS Column. 
7. Three washes of the column with 500 μL of buffer. 
8. Column was removed from the magnetic support and placed on a 15 mL tube 
for collection: 1 mL of buffer was added onto the column and the plunger 
was used to flush out the content. 
9. Repeating points 4 to 9 reduced the contamination by unwanted cells (with 
one new column). 
10.  
Cells expansion 
Expansion medium (or Chang Complete): MEM Alpha containing 20% Chang B+C, 
15% FBS, Penicillin, Streptomicyn and L-Glutamine. 
 
Selected cells were initially grown in a well of a 24-multiwell plate (BD Falcon©) 
and then – before confluence – they were split in another appropriate surfaces 
to maintain subconfluence (< 70-80%). 
 
Note: for both pre-selection passages and expansion process it was always used 
multiwell plates or petri dishes that were not “tissue culture” treated. 
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Freezing of cells were performed using FBS containing 10% Dimethyl sulfoxide 
(DMSO, Sigma©). 
 
Culture conditions and oxygen tension 
Cells were cultured under standard 20% O2, 5% CO2 and relative humidity of 95% 
level, referred as “normoxia” (using a Thermo Scientific Heraeus® CO2 incubator). 
Cells were also cultured under “hypoxia” with the environment at 5% O2 (using a 
CO2/O2 controller connected to a hypoxic chamber (Biospherix©) inside the 
above mentioned incubator). 
In vitro experiments 
Differentiation protocols 
Osteogenic 
Cells were seeded at a density of 4000 cells/cm2 on wells of 24-multiwell plates 
in Chang Complete. After 12 hours the cells were checked for adhesion and 
confluence (best ~80%), cells were washed once with PBS and medium was 
switched with the osteogenic one, composed by: 
– Dulbecco's Modified Eagle Medium (DMEM) Low Glucose 
– Penicillin and Streptomicyn 
– FBS       10 % 
– Dexamethasone (Sigma©)   100 nM 
– Beta-Glycerol Phosphate (STEMCELL©)  10 mM 
– Ascorbic acid 2-Phosphate (Sigma©)  50 µM 
Medium was changed every 4-5 days. 
 
Adipogenic 
Cells were seeded at a density of 4000 cells/cm2 on wells of 24-multiwell plates 
in Chang Complete. After 12 hours the cells were checked for adhesion and 
confluence (best ~80%), cells were washed once with PBS and medium was 
switched with the osteogenic one, composed by: 
– Dulbecco's Modified Eagle Medium (DMEM) Low Glucose 
– Penicillin and Streptomicyn 
– FBS       10 % 
– Insulin (Lilly©)     10  µg/mL 
– IBMX (3-isobutyl-1-methylxanthine, Sigma©) 1  mM 
– Dexamethasone     1  nM 
– Indomethacin (Sigma©)    60  µM 
Medium was changed every 4-5 days. 
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Endothelial 
Wells of 96- or 24-multiwell plates were coated with undiluted Matrigel™ 
Basement Membrane Matrix (BD Biosciences ©), respectively 50 or 200 µl, and 
then let stand in the incubator for one up to two hours. 
Cells were detached from the original expansion culture, resuspended and 
seeded over the solidified coating in EGM-2 (Endothelial Growth Medium-2, 
Lonza©). 30.000 cells were seeded for 24-multiwell plates and 5.000 cells were 
seeded for 96-multiwell plates. 
 
In vivo experiments 
Mice 
BALB/c strain Rag2-/- γc-/- immunodeficient mice were used In the experiments in 
order to avoid the possible rejection of our cells after xenotransplant. 
 
Matrigel plug 
A constant amount of cells were resuspended in 500 µl of Matrigel additioned 
with: 
Heparin (Pharmatex Italia©)   0.75  mg/mL final concentration 
Mouse recombinant FGFb (PeproTech©) 50  ng/mL final concentration 
Human recombinant VEGF (PeproTech©) 100  ng/mL final concentration 
Mice were anesthetised with isoflurane, via nose cone, and cold liquid Matrigel 
containing cells (or just PBS for controls) was injected in the back lumbar region 
of the animals (resulting in quasi immediate solidification). 
Mice were euthanized after 14 days by cervical dislocation and plugs were 
harvested for obtaining cryosections or measuring haemoglobin levels (after 
being snap-frozen in liquid nitrogen and stored at -80°C). 
 
Teratoma test 
Cells were injected either in the subcapsular space of the kidney after opening 
the animal on the abdominal side, or inside the tibialis anterior (TA) muscle of 
the hindlimb. 1 x 106 cells were injected in each test and organs were harvested 
nine weeks later. 
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Imaging 
Phase Contrast (PhC) and Bright Field (BF) pictures were taken using an 
Olympus© IX71 inverted microscope. 
Immunofluorescence (IF) pictures were acquired using a Leica© DMI 6000B 
inverted microscope. 
 
Spectrophotometry 
We used a SpectraMax Plus Spectrophotometer (Molecular Devices©) for 
measuring absorbance (or Optical Density, O.D.) of specific reactions (see later). 
 
Immunofluorescence 
For specific antibodies concentrations and conditions see APPENDIX A. 
IF protocol for cells grown in monolayer: 
1. Fix in para-formaldehyde (PFA, Sigma©) 4% in PBS, 10 minutes at room 
temperature. 
2. Wash briefly in PBS. 
3. Permeabilisation with Triton X-100 (Fluka©) 0.5% in PBS for 10 minutes. 
4. Wash in PBS two times for 5 minutes. 
5. Blocking of non-specific binding with PBS containing 3% Bovine Serum 
Albumin (BSA, Sigma©) for 30 minutes. 
6. Wash briefly in PBS. 
7. Incubate with primary antibody(-ies) in PBS containing 1% BSA. 
8. Wash in PBS three times for 5 minutes. 
9. Incubate with secondary antibody(-ies) in PBS containing 1% BSA. 
10. Wash in PBS three times for 5 minutes. 
11. Cells nuclei were counterstained with a mounting medium containing 49,6-
diamidino-2-phenylindole (DAPI) (Sigma-Fluoroshield™, Sigma-Aldrich©) or 
with Hoechst 33342 (Invitrogen©). 
 
IF protocol for cryosections: 
Tissue samples were processed in two different ways: 
• Frozen in liquid nitrogen: for entire organs or muscle samples (with 
isopentane cooling instead of submerging muscles inside liquid nitrogen). 
Fixation step before immunostaining as for cells grown in monolayer. 
• Fixed and dehydrated: for Matrigel plugs.  
Fixation for 1-2 hours in PFA 4% in PBS, dehydration at 4°C with sucrose 
gradient method: sucrose 10% in PBS for 1 hour, 15% for 1 hour and 30% 
overnight (O.N.). Then pieces were frozen in liquid nitrogen. 
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Subsequently cryosections were obtained after embedding samples in OCT 
(Kaltek©) and using a cryostat (Leica©) to produce transverse sections. 
 
1. Wash briefly in PBS. 
2. Permeabilisation with Triton X-100 0.5% in PBS for 10 minutes. 
3. Wash in PBS two times for 5 minutes. 
4. Blocking of non-specific binding with PBS containing 10% Horse Serum (HS, 
Gibco©) for 30 minutes. 
5. Wash briefly in PBS. 
6. Incubate with primary antibody(-ies) in PBS containing 1% BSA. 
7. Wash in PBS three times for 5 minutes. 
8. Incubate with secondary antibody(-ies) in PBS containing 1% BSA. 
9. Wash in PBS three times for 5 minutes. 
10. Cells nuclei were counterstained with a mounting medium containing DAPI 
(Sigma-Fluoroshield™, Sigma-Aldrich©). 
 
Immunocytochemistry 
Von Kossa 
To demonstrate calcium or calcium salts deposit inside wells after osteogenic 
induction Von Kossa staining was carried out. 
1. 24-multiwell plates well were fixed with PFA 4% for 30 minutes. 
2. Wash in distilled water twice for 5 minutes. 
3. Incubation for 1-2 hours under UV light after adding a 1% silver nitrate 
(Sigma©) aqueous solution. 
4. Wash in distilled water at least twice for 5 minutes. 
5. Remove of unreacted silver adding a 5% aqueous solution of sodium 
thiosulfate (Sigma©) for 5 minutes. 
6. Wash in distilled water for 5 minutes. 
7. Counterstain with Hematoxylin QS (Vector®) for 45 seconds and then rinse 
with tap water until the wash is colourless. 
8. Mount with aqueous mounting medium. 
Calcium deposits are substituted with observable brown/black precipitates of 
silver. 
 
Oil Red O 
To demonstrate accumulation of lipid droplets inside cells induced towards 
adipogenesis a coloration with Oil Red O (Sigma©), a lysochrome (fat-soluble 
dye), was used. 
MATERIALS AND METHODS 
 
35 
 
• Stock solution: Oil Red O 0.5% solution in isopropanol. 
• Working solution: 3/5 of Oil Red O Stock solution and 2/5 of distilled water. 
1. 24-multiwell plates well were fixed with PFA 4% for 30 minutes. 
2. Wash in distilled water twice for 5 minutes. 
3. Incubation for 30 minutes with Oil Red O working solution. 
4. Wash in distilled water at least twice for 5 minutes. 
5. Counterstain with Hematoxylin QS (Vector®) for 45 seconds and then rinse 
with tap water until the wash is colourless. 
6. Wells covered with distilled water until observation at brightfield microscope. 
 
Quantification 
Stained wells were washed 10 minutes with a Triton X-100 0.5% solution and 
then Oil Red O pigment was extracted from the stained lipids incubating 15 
minutes in agitation with isopropanol. 
The O.D. of the extracted dye was measured at 518 nm. 
 
Alkaline Phosphatase 
Following manufacturer’s instructions, Sigma-Aldrich© Alkaline Phosphatase kit 
was used for showing presence of Alkaline Phosphatase (AP) on surface of cells 
after osteogenic differentiation. 
Cells were fixed on bottom of the wells with Fixative Solution (2 volumes of 
Citrate Working Solution and 3 volumes of acetone) for 30 seconds and then 
rinsed in distilled water for 45 seconds. 
Fixed cells were incubated with Alkaline-dye mixture (FastBlue RR Salt solution 
plus Naphthol AS-MX Phosphate Alkaline Solution) for 30 minutes at Room 
Temperature (R.T.). 
After rinsing several times in distilled water nuclear counterstain was performed 
covering the bottom of the wells with Mayer’s Hematoxylin Solution for 10 
minutes. 
After rinsing in distilled water an aqueous mounting medium was used for later 
observation. 
 
Quantifications 
Calcium quantification 
After rinsing 2 times with distilled water, wells with cells in osteogenic 
differentiation were incubated overnight R.T. in agitation with 250ul of HCl 0.6N. 
Supernatant were collected and stored at -20°C (at least for 24 hours before 
quantification). 
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Calcium was quantified using Chema diagnostica© calcium kit and following 
manufacturer’s protocol. 
 
Haemoglobin quantification 
Matrigel Plugs were smashed with liquid nitrogen in a mortar and then the 
resulting powder was lysed in distilled water. 
Cells residue were pelleted and supernatants were used for haemoglobin (Hb) 
quantification using Drabkin’s Reagent (Sigma©). 
Lysates were incubated with Drabkin’s Reagent for 20 minutes R.T. 
Reaction product absorbance was read with spectrophotometer at 540 nm. 
 
Protein quantification 
Protein content of Matrigel plugs was obtained using Bradford Reagent (Sigma©) 
and following manufacturer’s instructions. Briefly: after incubating an aliquot of 
lysate (the same used for Hb quantification) with the reagent and incubating for 
30 minutes at R.T., proteins absorbance was read at 595 nm. 
 
Ac-LDL 
Human low-density lipoprotein (LDL) was used as a marker of endothelial 
differentiation as the acetylated (Ac) form of this apoprotein is taken up by 
microglial and endothelial cells that possess receptors specific for this modified 
LDL. This complex is also coupled with an Alexa Fluor® 488 dye that permits 
recognition by fluorescence. 
EGM-2 medium was taken out and replaced from the wells with an appropriate 
amount of fresh medium containing Alexa Fluor® 488 AcLDL (Molecular Probes®) 
at 10 µg/mL. After 6 hours of incubation medium was removed, cells were 
washed in PBS and then fixed for later observation with PFA 4% for 15 minutes. 
Cells nuclei were counterstained with Hoechst 33342. 
 
Proliferation curves and doubling time 
An equal amount of cells were seeded on multiwall plates at the same time for 
later counting the increased number of cells. At determined time points the cells 
were: 
1. fixed with PFA 4% for 15 minutes 
2. washed in PBS twice for 5 minutes 
3. a brief permeabilisation was carried out with Triton X-100 0.5% in PBS for 5 
minutes 
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4. after a brief wash cells nuclei were stained with Hoechst 33342. 
Cells numbers were evaluated counting the nuclei on a series of randomised 
fields for the different samples and for each time point. 
 
Flow Cytometry 
Cells in culture were detached by trypsinisation and then incubated with specific 
antibodies following manufacturer’s indications on quantities. 
Cell suspensions were incubated 20’ at 4°C in the dark. 
After a wash step the cells were resuspended in a suitable volume of PBS and 
fluorescence emission was detected using a FACSCalibur™ (BD Biosciences©) 
flow cytometer. 
Acquired data were analysed using FlowJo software (TreeStar Inc.©) after gating 
on viable cells. 
Cells analysed starting from freshly retrieved AF samples were not trypsinised 
but were instead filtered through 70 µm nylon mash filter and then stained as 
described above. 
 
Cell cycle analysis 
PI staining 
Propidium Iodide (PI) was used to stain the genetic material inside each single 
cell and discriminate the cell cycle phase in base of the amount of DNA, relative 
fluorescence of the bound molecule was acquired by flow cytometry and this 
indirectly gave information on DNA content. 
PI staining solution: 
– PBS 
– Triton X-100    0.1 % 
– DNAse-free RNAse A (Sigma©)   0.2  mg/mL 
– PI (Sigma©)    1  mg/mL 
1. Cells were detached by trypsinisation and then centrifuged in PBS at 200 x g 
for 5 minutes at 4°C. 
2. Pellets were resuspended in 1 mL of cold PBS per billion of cells. 
3. Cell suspension was added dropwise while stirring a tube with an equal 
volume of absolute cold ethanol; tubes were stored at -20°C for at least one 
day before proceeding with the staining. 
4. Cells were washed once with cold PBS at 200 x g for 10 minutes at 4°C. 
5. Staining was performed adding 300 µl of staining solution per billion of cells. 
6. After incubation at 37°C for 15 minutes cells were analysed at the flow 
cytometer. 
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Gene expression 
RNA extraction 
Total RNA was extracted using RNeasy “Micro” or “Mini” Kit (Qiagen©) in base of 
calculated number of starting material, procedures was conducted following the 
manufacturer’s instructions. 
RT-PCR 
RNA extracted was retrotranscribed (RT) using: 
– SuperScript® II Reverse Transcriptase (Invitrogen™). 
– Oligo(dT)12-18 as primer for reaction (Invitrogen™). 
– RNAse H (Invitrogen™) for eliminating DNA-RNA hybrids after reaction. 
All procedures were carried out based on manufacturer’s instructions and using 
GeneAmp® 2720 thermal cycler (Applied Biosystems®). 
 
Synthetized cDNA was quantified for downstream application using a Nanodrop 
ND-2000 Spectrophotometer (Thermo Scientific©). 
 
Polymerase chain reaction (PCR) for target genes were performed using 
recombinant Thermus aquaticus (Taq) DNA Polymerase system (Invitrogen™) 
with specific primers (see APPENDIX B). 
PCR products were analysed by electrophoresis in agarose gel 1-1.5% in TBE 1× 
Buffer (54 g of Tris base, 27.5 g of boric acid, 20 ml of 0.5 M EDTA) containing 
SYBR® Safe DNA gel stain (Invitrogen™). 
 
RealTime PCR 
Quantitative RealTime PCR (qPCR) was performed using Platinum® SYBR® Green 
qPCR SuperMix-UDG (Invitrogen™) and reactions have been carried out in a 
LightCycler II instrument (Roche©), using 5 ng of cDNA and a 300 nM mix of 
specific forward and reverse primers (final concentrations). 
Results have been expressed in Arbitrary Units (A.U.) considering the ratio of 
targeted gene mRNA content and a housekeeping gene (human β2 
microglobulin, abbreviated “B2M”) mRNA content. 
 
Angiogenesis 
Matrigel network formation was analysed and quantified with ImageJ software 
(Rasband, 1997) coupled with Carpentier G. Angiogenesis Analyzer (2012) 
available online  
(http://imagej.nih.gov/ij/macros/toolsets/Angiogenesis%20Analyzer.txt).
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RESULTS 
Second trimester AFSCs 
Here is a brief scheme illustrating the procedure followed to isolate CD117+ 
AFSCs from AF primary cultures (Figure 13). 
 
Figure 13 
As already confirmed in previous works (Gosden, 1983) the number of cells 
inside AF samples is very variable and non-constant, without a clear correlation 
between retrieved volume and number of cells (see Figure 14). 
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Figure 14 Correlation study between AF retrieved volumes and cells content. 
 
Cells isolated from AF samples showed also a very heterogeneous positivity for 
some surface markers and numbers of viable cells (negative for the cell viability 
stain with 7-Aminoactinomycin D (7AAD)) (see Figure 15). In particular high 
variability was observed for our marker of interest CD117 (see Figure 16). A 
mean of 5.3 % of CD117+ cells were present among the samples, with variations 
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ranging from almost zero to a fifth of the total number of viable cells. 
Interestingly this percentage even if not from a very large statistical group is 
higher compared to those reported in literature (Klemmt et al., 2011).  
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Figure 15 Percentage of cells stained positive for some markers and viability (7AAD -) by flow citometry. 
Each line connecting the values reppresent a single analysis for that sample. 
 
Figure 16 Flow cytometry histograms showing the percentage of CD117 positive expression in freshly 
retrieved AF. 
 
After plating the cells over glass coverslips and culturing them for some days, the 
resulting morphology was different among samples: some presented a majority 
of floating round- or cuboidal-shaped aspect and no adhesion was observed 
(Figure 17 A), others presented a mixed morphology with few adherent cells low-
proliferating and some floating (Figure 17 B), in some cases the percentage of 
adherent and well proliferating cells were higher (Figure 17 C). In some cases an 
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epithelial-like morphology was observed, these cells did not yield AFSCs after 
positive selection for CD117 (Figure 17 D). 
 
Figure 17 Morphology of primary culture of AF samples showing different populations of amniocytes in PhC 
(original magnification 10X). 
Cells selected for CD117 maintained proliferative potential and the same 
morphology after selection, in Figure 18 it can be seen a typical morphology after 
immune-selection compared to a primary culture showing same-aspect cells 
(Figure 17 C, white circles). 
 
Figure 18 PhC images of AFSCs after selection for CD117 and in expansion medium (original magnification 
20X). 
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Expression of CD117 (as already confirmed in our experience and also from other 
authors) was diminished after expanding cells in culture and after few passages 
no detectable protein was found either via flow cytometry (Figure 19 A) or IF 
(Figure 19 B). Interestingly at passage 2 (P2) the protein was not detectable on 
the surface and it rather seems to localise in the cytoplasm, later on (P4-P5) only 
few rare cells were still positive. It is known that CD117 positive cells also express 
Oct4 (a nuclear transcription factor known to identify pluripotent stem cells, also 
one of the factors used by Yamanaka first to generate iPS cells) as already 
demonstrated in previous works (De Coppi et al., 2007) in expanded AFSCs there 
is no detection of the protein. Among other marker for pluripotency the only two 
found after expansion were SSEA4 and KLF4 (see later, Figure 22). 
 
 
Figure 19 CD117 expression in expanded AFSCs. A: expression of surface marker by flow cytometry. B: IF 
staining at different passages (n=3) (original magnification 4X and 20X). 
Third trimester AFSCs (and comparison with 2nd trimester) 
AFSCs cells from the third (3rd) trimester contain CD117+ cells (Figure 20 A) that 
could be identified on primary culture of AF. Morphology resembled that of 
second (2nd) trimester counterpart (Figure 20 B, right columns), staining for 
CD117 revealed positivity before selection (Figure 20 B, right column) and 
expanded culture yielded same morphology as well. 
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Figure 20 A: flow cytometry of fresh 3rd trimester AF cells after gating on viable cells (7AAD-). B: images of 
unselected cells in primary culture of 3rd trimester. Left panel: PhC of AF cells (original magnification 20X). 
Right panel: IF staining for CD117 (original magnification 40X). 
Fresh samples of AF from 2nd and 3rd trimester were analysed for surface markers 
just after collection, half sample was seeded in culture and the other half was 
stained for specific antigens (Figure 21). 
Cells from both trimesters are in the majority negative for CD29, CD31 and 
CD271, except for some CD117+ cells of the 3rd trimester which are positive for 
those three markers. CD45, CD34, CD166, CD56 and HLA-DR are not expressed in 
both trimesters (except a little population CD117- positive for CD56). CD117+ 
cells from both trimesters are slightly positive for CD184 and HLA-ABC. CD117+ 
fraction is also positive for mesenchymal markers as CD105, CD90, CD73, the 
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receptor for hyaluronic acid CD44 and CD146. CD117- fraction also presented 
positivity for CD73. The main difference noticeable in freshly collected samples 
from the two trimesters is about the expression of CD9: both present expression 
of this molecule but 2nd trimester cells seems to not co-express CD117 and CD9 
whereas in 3rd trimester the cells positive for CD117 are always double-positive 
CD9+CD117+. CD9 is a molecule known to act in processes like motility, activation 
of cells (especially in platelet activation and aggregation, also cells releasing 
histamine are CD9+), growth and development (Mazzocca et al., 2002; Le Naour 
et al., 2000; Runge et al., 2007). More interestingly CD9 is known to associate at 
the membrane with other molecules at some extent and between those there is 
also CD117 (Anzai, 2002). 
 
Figure 21 Flow cytometry characterisation of freshly collected AF cells of 2nd and 3rd trimester. Plots 
representing specific markers (Y axis) versus CD117 expression (Y axis) after gating for excluding dead cells 
(7AAD+). Isotype controls and threshold axes in grey. 
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As already investigated for 2nd trimester AFSCs, expression of pluripotency 
marker SSEA4 and KLF4 was confirmed, the first showed a reduced percentage of 
expression in expanded cells whereas the second is expressed in trimesters’ 
AFSCs at similar levels (Figure 22). 
 
Figure 22 Counts and relative sample images for cells stained by IF for presence of pluripotency markers 
SSEA4and KLF4 (counts on randomised fields, % positive cells = positive cells / total DAPI positive cells) (n=3; 
**p < 0.01). 
Hypoxia 
Two different hypoxic concentrations were tried: 2% O2 and 5% O2. 2% was first 
used because in a recent study of our group we demonstrated the effect of this 
oxygen tension on satellite cells (small progenitor cells found in the muscle) 
(Urbani et al., 2012). No growing or attaching cells were observable with this 
condition so 5% of oxygen was tried and with successful isolation of AFSCs (see 
Figure 23). 
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Figure 23 PhC images of AF cells primary culture showing typical morphology at different concentration of 
oxygen and between the two trimesters (original magnification 10X). 
After growing and selecting primary AFSCs cultures in one or the other oxygen 
concentration, it was also tried to switch (simply by moving the culture 
petri/multiwell) to the other condition but cells did not survive this change and 
stopped proliferating undergoing senescence after some time. 
A comparison of the proliferation rate between the two conditions of oxygen and 
the two trimesters was performed: a defined number of cells were plated at “day 
0” and then at determined time-points cells on the bottom of the wells were 
fixed and DAPI positive cells were counted. The proliferation was expressed in 
terms of fold-change compared to the day of seeding (see Figure 24 A). After that 
it was calculated also the doubling time in those culture conditions (see Figure 24 
B). Hypoxia greatly influences cell proliferation, augmenting the yields of cells of 
almost 7 times, confirmed by doubling time reduction. Between trimesters there 
was no observable differences in terms of proliferation when cultured at the 
same oxygen tension. 
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Figure 24 A: counts of cells during culture at time-points for proliferation rate. B: calculated doubling time 
based on cell number at different time-points (n=5; *p < 0.05, **p < 0.01, ***p < 0.001). 
Also the cell cycle were analysed at the same moment of proliferation, using PI 
to stain genetic material and discriminate between phases in relation to the 
amount of DNA present in each cell (Figure 25). Surprisingly no appreciable 
differences among trimesters or oxygen conditions were observed. 
RESULTS 
 
48 
 
 
Figure 25 Cell cycle results between trimesters and conditions of oxygen (n=5). 
 
KLF4 pluripotency marker was investigated and again found expressed in AFSCs 
cultured in 5% oxygen tension with similar levels to those expanded under 
normoxia for both trimesters (Figure 26). 
 
Figure 26 Images of cells stained by IF for presence of pluripotency marker KLF4. 
A comparison between hypoxia and normoxia was also conduced on the same 
markers for flow cytometry used in freshly collected samples. Here there are 
summarised the results grouped by trimesters showing overlay between 20 and 
5% of oxygen (Figure 27). Primarily this was done to see the difference of 
markers expression after expansion and compare them to freshly collected AF 
samples (Figure 21). A summarised table of the results for each trimester is 
found in Table 2. 
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The phenotype is changed compared to freshly collected samples, concentrating 
on the original CD117+ population the differences are related to upregulation of 
some molecule: 
• CD29: some cells were already positive in 3rd trimester. 
• CD271: some cells are positive in both trimesters, before only in 3rd trimester. 
• CD90 and CD73: increased positivity in hypoxic-expanded 2nd trimester cells. 
• CD105: increased positivity in hypoxic-expanded cells. 
• CD166: upregulated in expanded cells (more in hypoxic-expanded 2nd 
trimester). 
• CD9: 2nd trimester cells became also positive after expansion. 
• CD56: slight upregulation, hypoxia seems to reduce expression in 3rd 
trimester. 
  2nd trimester  3rd trimester 
Marker 
 AFTER 
EXPANSION 
COMPARISON 
TO FRESH 
HYPOXIA 
EFFECT 
 AFTER 
EXPANSION 
COMPARISON 
TO FRESH 
HYPOXIA 
EFFECT 
CD29  + > >  + >= = 
CD271  +/- = =  +/- = = 
CD90  + = >  + >= = 
CD73  + >= >  + >= = 
CD31  - = =  - = = 
CD105  + > >  + = > 
CD146  + >= =  + >= = 
CD166  + > >  + > = 
CD44  + = =  + >= = 
CD184  +/- = =  +/- = = 
CD9  + > =  + = = 
CD56  +/- > =  + > <= 
CD45  - = =  - = = 
CD34  - = =  - = = 
HLA-ABC  + >= =  + >= = 
HLA-DR  - = =  - = = 
Table 2 results and comparison of AFSCs phenotyping after expansion. + and -: positive and negative; +/- 
around 50% of positivity; > and <: increased and reduced positivity. Grey cells represent major observable 
differences. 
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Figure 27 flow cytometry phenotype of 2nd trimester (A) and 3rd trimester (B) AFSCs between 20 and 5% of 
oxygen culture. 
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Osteogenic differentiation 
To evaluate osteogenic differentiation Von Kossa staining was performed to 
show calcium deposit in culture (Figure 28), then detection of Alkaline 
Phosphatase enzyme (ALP, Figure 29) was carried out: both marker of occurring 
osteogenesis. It results that cells can differentiate to a stage where they can 
deposit calcium deposits that are found in culture and are appreciable both by 
specific stainings but also the macroscopic appearance of the bottom of the well 
looked like some deposit were present (Figure 30 A). Calcium present in each 
well at different time-points was then quantified (Figure 30 B), 3rd trimester cells 
present higher quantities of calcium at the final day of the culture (day 21). Also 
some osteogenic genes have been investigated by RT-PCR (Figure 30 C) showing 
that differentiated cells express the late osteogenic marker Osteocalcin and still 
express RUNX2 (involved in osteogenic lineage maturation), this last one was 
interestingly found also on the undifferentiated cells, meaning that maybe they 
are prone to differentiate into osteoblasts having this gene already expressed. 
 
Figure 28 top rows: Von Kossa staining on 2nd and 3rd trimester AFSCs differentiated in osteogenic lineage; 
bottom rows: controls, undifferentiated cells (original magnification 10X). 
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Figure 29 (LEFT) ALP staining 
on the surface of cells during 
culture, images of peak point 
at day 15 during 21 days of 
osteogenic differentiation 
(original magnification 10X). 
 
 
 
 
 
 
 
Figure 30 (BOTTOM) A: macroscopic aspect of differentiated and undifferentiated AFSCs towards 
osteogenic lineage at day 21. B: calcium quantification during osteogenic differentiation in a 24-multiwell 
plate (n=3; **p < 0.01). C: specific RT-PCR products after electrophoresis in gel of agarose. 
Adipogenic differentiation 
Adipogenic differentiation was tried both in normoxia and in hypoxia, after 21 
days Oil Red O staining was performed to mark lipid droplets inside what seemed 
to be pre-adipocytes (Figure 31). 
Then the dye was extracted from lipids and the absorbance quantified by 
spectrophotometry (Figure 32). As it seems, adipogenesis is achieved in both 
oxygen tensions but with contrasting results: at 5% more cells (or more mature 
lipid vacuoles) are bounded to the specific dye (yielding a higher absorbance 
after extraction) for 2nd trimester cells, on the contrary AFSCs from the 3rd 
trimester show less accumulation of Oil Red O. 
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Figure 31 Oil Red O staining on differentiated 2nd and 3rd trimester AFSCs in different oxygen tensions at day 
21 (original magnification 20X, 40X for inserts). 
 
Figure 32 Ratio sample/control (undifferentiated) of extracted Oil Red O absorbance at 518 nm between 
trimesters and oxygen concentrations (n=3; *p < 0.05, **p < 0.01, ***p < 0.001). 
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Endothelial differentiation 
In vitro 
Capillary like structures were formed after using AFSCs in the endothelial cell 
tube formation assay on basement membrane (Arnaoutova et al., 2009). These 
meshes were photographed in PhC microscopy (Figure 33) and then analysed. As 
positive control for the assay, and to obtain a comparable standard, the assay 
was performed with HUVEC (Figure 34) (Park et al., 2006). 
Imaging analysis revealed that the average area of meshes were comparable to 
those of control cells (Figure 34, “Tot. meshes area”) whereas the total number 
or branches left outside of closed mashes seemed reduced in hypoxia (Figure 34, 
“Branching interval”). Also, considering the mean size and the abundance of the 
meshes in each condition the hypoxic condition seemed to favourite a higher 
number of complete structures compared to normoxia (Figure 34, “Mesh index” 
and “Mean Mesh Size”). For a complete view of analysed parameters see 
Appendix C. 
To test if those structures were possessing endothelial markers, IF for von 
Willebrand Factor (vWF) was performed (Figure 35) and also verified the ability 
of those cells to uptake AcLDL in culture (recognizable later because of a 
fluorophore attached to the molecule) (Figure 36). Cells from both trimesters 
were showing positive staining for vWF both in normoxia and hypoxia. AcLDL 
uptake was observable as fluorescent vacuoles after 6 hours of incubation in 
both trimesters and concentrations of oxygen. 
Gene expression analysis by RealTime PCR was also performed after endothelial 
induction on tube formation assay on Matrigel (Figure 37). HUVEC and CB-
derived mononuclear cells were used as positive controls. 
These genes were chosen because of a recent published article  describing their 
implication on commitment and role in endothelial differentiation of progenitors 
and reprogrammed cells (Ginsberg et al., 2012). 
Basal levels of ETV2 were detectable in all conditions, after endothelial 
differentiation ETV2 was downregulated for hypoxic 3rd trimester and instead 
upregulated for 2nd trimester hypoxic. 
FLI1 was present in small quantity on basal normoxic condition, whereas in 
hypoxia it was more expressed, after differentiation FLI1 decreased in expression 
on hypoxic conditions reaching levels similar to that of basal normoxic 
conditions. Almost no expression was detectable in normoxia after endothelial 
induction.  
ERG1 was almost no detectable in hypoxia cultivated and differentiated cells, 
also basal level in normoxia expanded cells is very low but and upregulation is 
observed after endothelial differentiation. 
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Figure 33 PhC images of AFSCs from 2nd and 3rd trimester after tube formation assay on Matrigel 18h after 
seeding (original magnification 10X). 
  
Figure 34 Calculated values by interpolation of PhC images of AFSCs after tube formation assay on Matrigel. 
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Figure 35 IF showing expression of vWF on differentiated AFSCs (Hoechst as nuclear counterstain).  
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Figure 36 PhC and fluorescence images showing AcLDL (green) uptake by tubular structures formed by 
AFSCs (Hoechst as nuclear counterstain). 
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Figure 37 RealTime PCR analysis on AFSCs after tube formation assay on Matrigel. Starting from the left on 
the histograms: HUVEC (FLI1 and ERG1) or hCB (ETV2) as positive controls, 2nd trimester before and after 
endothelial differentiation assay, 3rd trimester before and after endothelial differentiation assay (plots show 
relative expression normalised to housekeeping gene B2M; *p < 0.05, **p < 0.01, ***p < 0.001). 
In vivo 
Matrigel plugs were harvested from subcutaneous areas of injection after two 
weeks. Pictures were taken (Figure 38 Aii and Aiii) and then the plugs were either 
fixed in PFA for immunostaining of snap-frozen for haemoglobin quantification. 
Evident formation of new vases was observable inside plugs injected with cells 
(Figure 38 Ai). 
Haemoglobin content was then measured for each condition and normalised for 
the quantity of total proteins in each sample (Figure 38 B). Cells from the 2nd 
trimester expanded in 5% of oxygen gave the highest Hb content compared to 
the others. Haemoglobin content gives a relative functionality measure of new 
vases formed inside the Matrigel plugs, meaning that new circulation was 
brought inside the implanted material, this do not exclude that newly formed 
vases derive from the host instead of the injected cells so immunostainings to 
confirm the contribute of AFSCs to angiogenesis was performed. 
Sectioned plugs containing cells presented vases staining positively using 
antibodies against specific human von Willebrand Factor protein; to be sure in  
identifying the injected cells, sections were stained also with an antibody against 
human mitochondria. In Figure 38 C there is a representative image of a circular 
structure co-expressing the two antigens. 
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Figure 38 In vivo angiogenesis of AFSCs. A: representative image of Matrigel plug appearance on 
subcutaneous injection site (i) and pictures taken after excision of a control (ii) and a plugs with cells (iii). B: 
haemoglobin quantification showing fold-change of Hb normalised to total protein content and control 
plugs (without cells) (**p < 0.01, n=3). C: IF on sectioned Matrigel plug containing AFSCs (original 
magnification 40X). 
 
Teratoma test 
No evident teratoma formation was found by morphological and histological 
analysis.
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DISCUSSION 
In this work it was successfully standardised a method for isolating AFSCs starting 
from freshly collected samples. This technique isolate specifically CD117+ cells in 
primary AF cultures and then expand them in great scale maintaining their 
original mesenchymal-like morphology and potential. 
Samples from 3rd trimester gestational age were also able to give rise to the 
same population when cultured with this method. 
A phenotypic characterisation of cells deriving from 2nd or 3rd trimester showed 
great similarity between the two sources of cells but also some differences have 
been noticed. 
The main phenotypic differences are about the expression of CD271 which is 
present in the CD117+ cells from the 3rd trimester but not in the 2nd trimester. 3rd 
trimester whole population also shows higher level of CD73 in both CD117+ and 
CD117- fractions. Some HLA-DR positive cells are detectable in the CD117- 
fraction of 3rd trimester AF cells. 
But the most remarkable difference – as already told – is about the expression of 
CD9. The presence of two distinct population positive for one or the other 
marker (CD9+ or CD117+) in 2nd trimester AFSCs may indicate an intermediate 
stage where the CD117 positive population has yet to express CD9, maybe later 
during the gestation period (like in 3rd trimester AFSCs) they will start to express 
this marker; this is based also on the fact that cells are presenting the antigen 
after expansion without compromising some of their differentiation 
characteristics. Almost certainly a double-positive CD9+CD117+ population is still 
of interest, thus CD9 should not be included in some lineage depletion procedure 
with specific antibodies (even if it is a common marker of adult cells (e.g. 
mastocytes)); this is particularly important for 3rd trimester AFSCs where 
eliminating CD9+ cells would mean also to remove the CD117 fraction. 
The same phenotyping, performed after selection and identification of wanted 
cells, revealed a change in the markers present at the surface of expanded cells. 
In contrast to fresh samples the expanded cells levelled the differences between 
trimesters, just for the exception of CD56 which remained not expressed in 2nd 
trimester whereas became expressed in 3rd trimester AFSCs. 
The effect of hypoxia on surface marker expression was most appreciable on 
CD105 that was nearly present in all cells when cultured at 5% of oxygen, in 
contrast to normoxia where positivity percentage was variable. 
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The already told difference in CD56 expression was diminished under hypoxic 
condition: 3rd trimester CD56+ cells were about half compared to normoxia. Still, 
2nd trimester AFSCs express very low percentage of CD56+ cells. 
2nd trimester cells also upregulated more CD29, CD90, CD73 and CD166 when 
cultured in hypoxia than in normoxia. 
Interestingly CD9 profile after expansion resulted quasi identical (both expressed 
this surface molecule) despite the initial differences in fresh samples. 
Pluripotency markers are expressed in both trimesters after expansion also at 
different oxygen concentration, notably KLF4 is counted for the majority of 
AFSCs cells whereas SSEA4 is more present in 2nd trimester cells at initial 
passages and equalise with 3rd trimester later in culture. 
Also the proliferation rate among the two is similar during normoxic condition, 
instead when placed in in 5% of oxygen an increase of proliferation for both is 
noticed. A reduced doubling time was not observed to couple with a variation in 
percentage of cells into different phases of the cell cycle, so the cells still 
maintain the proportions of the different phases during mitosis but probably the 
cells are cycling more rapidly. Time-lapse microscopy is being performed to 
answer to that question with more certainty, still it remains a fact that expanding 
cells in hypoxia greatly increase the number of cells that can be obtained after 
expansion of a single sample of AF. The later experiments on phenotype 
characterisation and potential of differentiation were made to verify the potency 
between trimesters and also see if a difference was observable when culturing 
the cells in 20% or 5% oxygen tension. 
Osteogenesis is achieved from cells of both trimesters, quantification of calcium 
deposition show a higher capacity of mineralisation by 3rd trimester AFSCs, both 
presented Osteocalcin expression (a marker of late osteogenesis) and still 
expressed RUNX2 after 21 days of differentiation. Macroscopic appearance also 
seems to confirm those results. 
Osteogenic differentiation was not performed in 5% of oxygen because it is 
known that hypoxic environment inhibit this type of induction with a well-known 
method: during hypoxic condition the HIF-1α subunit of the Hypoxia-inducible 
factor-1 (HIF-1) factor is upregulated and among other effects in cell metabolism 
it results in the activation of the HIF-TWIST pathway that ultimately leads to 
downregulation of the osteogenic gene RUNX2. Without RUNX2 cells are not 
able to underwent osteogenic differentiation also because RUNX2 is necessary to 
activate others osteogenic specific genes like Osteopontin and also Alkaline 
Phosphatase activity is reduced (Tsai et al., 2012). 
Adipogenic potential is also conserved among cells of both trimesters but with 
inverted tendencies. 3rd trimester show a higher rate of differentiation 
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(comparing the size of lipid droplets and the number of differentiated cells) in 
normoxia, whereas if adipogenesis is performed at 5% of oxygen there are few 
cells showing positive staining. On the other hand the hypoxic condition seems 
to increase the quantity of cells differentiated from 2nd trimester AFSCs,  where 
instead 20% of oxygen results are comparable to those of 3rd trimester at 5% 
(low differentiation). In literature there are contrasting opinions about the 
benefits of oxygen conditions in adipogenesis, it has to be noticed that in some 
work on reduced adipocyte differentiation is described but they also use a very 
low concentration of oxygen (1%) (Carriere et al., 2004), other authors  instead 
describe a potent adipogenic effect exerted by hypoxic conditions (Chung et al., 
2009a) so it is probable that oxygen levels are important for adipocytes 
formation but maybe a dynamic combination of O2 tensions and specific 
differentiation pathways are not easily reproducible during in vitro assays. 
About angiogenic potential it was demonstrated that 5% of oxygen permits 
angiogenesis. Considering the well characterised HUVEC population as a control 
for endothelial committed cells, it seems that during cell tube formation assay 
the AFSCs cultivated in hypoxia form structures more similar to HUVEC than the 
counterpart cultivated in normoxia. Interestingly it can be postulated that AFSCs 
are plastic enough to have the angiogenic program opened and ready to act, 
considering the low amount of time needed to generate endothelial-like cells 
also from the functional point of view (AcLDL uptake). Gene expression reveals 
that AFSCs have very high levels of ETV2 present constitutively, this is a key 
regulator for commitment into endothelial lineage (whereas HUVEC do not 
present this transcript natively because they are fully committed, Cord Blood 
endothelial progenitors show instead very little expression of ETV2 compared to 
AFSCs). Also FLI1, which is typical of a more mature endothelial cell, is expressed 
in AFSCs: very low levels are expressed in normoxia-cultivated cells and it is 
downregulated after tubule formation assay, hypoxic-cultivated cells show 
higher expression of FLI1 before induction and they also present down regulation 
after. These two genes and their specific levels of expression may be enough to 
maintain AFSCs in a state of pre-endothelial cells (but as already demonstrated 
they are not fully committed because of their ability to differentiate also in other 
lineages). Notably ERG1 is instead not expressed in AFSCs cultivated and 
differentiated in hypoxia, also normoxic-cultivated cells do not express ERG1 but 
they present an upregulation after endothelial differentiation. This gene has 
been demonstrated not to be expansible for endothelial differentiation 
(Ginsberg, Cell 2012), it is instead required for cell commitment; considering that 
cells were analysed at day 0 and day 3 after induction it should be interesting to 
evaluate the presence of this gene in between the 72 hours of differentiation for 
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the hypoxic condition and see if the upregulation in normoxia is instead the 
residue of a transient expression in early stages of culture. 
When comparing the in vivo results of AFSCs it is clear the difference on de novo 
angiogenesis of cells compared to controls. A striking formation of new vases is 
encountered when injecting cells from the 2nd trimester expanded in hypoxia, 
this could be related to the specific presence of ERG2 and FLI1 in these cells, 
strangely 3rd trimester expanded at 5% of oxygen did not yield a similar result 
even sharing the same pattern of expression for these three genes; considering 
the high upregulation of ERG2 on 2nd trimester AFSCs during in vitro assays, one 
can hypothesise that induced progenitors proliferate and develop more when 
compared to those of the hypoxic-cultivated 3rd trimester cells (which has a 
downregulation of ERG2 in vitro after induction). 
About safety on perspective use of these cells in regenerative medicine 
purposes, no teratoma was found when these cells were injected into 
immunodeficient recipients. 
Concluding, it was demonstrated that AFSCs can be isolated from AF samples not 
only from mid gestational period after amniocentesis but also from samples of 
the final period of pregnancy. This is very important because amniocentesis is 
becoming more rare and so here is reported a method for collecting and 
obtaining AFSCs during childbirth, without particular effort or ethical concern 
considering that AF is usually discarded during delivery. 
AFSCs deriving from both trimesters shows similarity about phenotype and 
potency of differentiation. 
Moreover some beneficial effect of hypoxia in cultivating AFSCs have been 
described. Cells expanded in 5% of oxygen also showed a pronounced effect on 
angiogenesis in vivo, more evident in 2nd trimester cells. 
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APPENDIX A 
Antibodies used for flow cytometry and relative manufacturer, concentrations 
and application following original specifications. 
ANTIBODY MANUFACTURER 
CD29 Biolegend© 
CD271 Miltenyi Biotec© 
CD90 Biolegend© 
CD73 Biolegend© 
CD31 Biolegend© 
CD105 Beckman Coulter© 
CD146 BioCytex™ 
CD166 Beckman Coulter© 
CD44 eBioscience© 
CD184 Beckman Coulter© 
CD9 Biolegend© 
CD56 Beckman Coulter© 
CD45 BD Pharmingen© 
CD34 Miltenyi Biotec© 
HLA-ABC Beckman Coulter© 
HLA-DR Beckman Coulter© 
Antibodies used for immunofluorescence, relative manufacturers, dilutions and 
conditions in which they were used. 
 MANUFACTURER DILUTION 
INCUBATION TIME 
- 
TEMPERATURE 
PRIMARY ANTIBODIES    
CD117 Santa Cruz Biotechnology© 1:80 1 h – 37°C 
SSEA4 Abcam© 1:80 1 h – 37°C 
KLF4 Santa Cruz Biotechnology© 1:50 O.N. – 4°C 
von Willebrand Factor Dako© 1:100 1 h – 37°C 
Human mitochondria Abcam© 1:80 1 h – 37°C 
SECONDARY ANTIBODIES    
Alexa Fluor® 594 Goat 
Anti-Mouse 
Molecular Probes® 1:150 1 h – 37°C 
Alexa Fluor® 488 Goat 
Anti-Mouse 
Alexa Fluor® 594 Chicken 
Anti-Rabbit 
Alexa Fluor® 488 Chicken 
Anti-Rabbit 
APPENDICES 
 
ii 
 
APPENDIX B 
Primers forward (Fw) and reverse (Rv) used for RT-PCR and/or RealTime PCR: 
TARGET GENE SEQUENCE (5’->3’) 
RUNX2 
Fw AGAGGTACCAGATGGGACTGTGGTT 
Rv GGTAGCTACTTGGGGAGGATTTGTG 
Osteocalcin 
Fw TGAAGAGACCCAGGCGCTA 
Rv GATGTGGTCAGCCAACTCGTC 
β2 Microglobulin 
Fw GCTGTGCTCGCGCTACTCT 
Rv CAACTTCAATGTCGGATGGATG 
ETV2 
Fw CCGACGGCGATACCTACTG 
Rv GTTCGGAGCAAACGGTGAG 
FLI1 
Fw GAGGAGCTTGGGGCAATAAC 
Rv AGAGCAGCTCCAGGAGGAAT 
ERG1 
Fw TGCTCAACCATCTCCTTCCA 
Rv TGGGTTTGCTCTTCCGCTCT 
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APPENDIX C 
